Skip to main
COLL

Collegium Pharmaceutical (COLL) Stock Forecast & Price Target

Collegium Pharmaceutical (COLL) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Collegium Pharmaceutical is poised to continue its strong growth in the biopharmaceutical industry due to its diversified product portfolio for the treatment of ADHD and moderate to severe pain. The company's recent guidance, increase in its Jornay PM sales estimates, and expansion of its sales force and digital efforts all point to strong potential for revenue growth in 2026 and beyond. Additionally, with a strong operating cash flow margin and the recently-enhanced balance sheet, the company is well-positioned for potential business development opportunities and creating shareholder value. Despite potential pressure from generic competition in the Nucynta franchise, we maintain our Buy rating and raise our price target to $60 from $46.

Bears say

Collegium Pharmaceutical is facing potential challenges with generic erosion on its pain portfolio, which could impact future revenues and overall profitability. Despite efforts to pursue potential acquisitions through a newly obtained credit facility, the company's heavy reliance on third-party suppliers for its DETERx technology raises concerns about potential disruptions in the commercialization of its products. Furthermore, the company's current financials show increasing costs of goods sold, which could further impact its profitability in the long run.

Collegium Pharmaceutical (COLL) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Collegium Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Collegium Pharmaceutical (COLL) Forecast

Analysts have given Collegium Pharmaceutical (COLL) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Collegium Pharmaceutical (COLL) has a Strong Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Collegium Pharmaceutical (COLL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.